《2022 AHA/ACC/HFSA心力衰竭管理指南》解读:心力衰竭新理念和心外科关注点

Interpretation of 2022 AHA/ACC/HFSA guideline for the management of heart failure:New concepts of heart failure and cardiac surgery concerns

“2022年AHA/ACC/HFSA心力衰竭管理指南”(以下简称“2022指南”)取代了“2013年ACCF/AHA心力衰竭管理指南”和“2017年ACC/AHA/HFSA重点更新2013年ACCF/AHA心力衰竭管理指南”。2022指南旨在为临床医生提供以患者为中心的推荐,以预防、诊断和管理心力衰竭。心力衰竭仍然是全球具有高发病率和高死亡率的主要心血管疾病。2022指南基于当前证据更新了治疗推荐。这些推荐提出了一种基于证据的方法来管理心力衰竭患者,目的是提高监护质量,并符合患者利益。在已公布的证据支持下,提出了新的建议,并通过已发表的高质量成本效益研究为某些临床处理提供了价值陈述。本文对2022指南中心力衰竭的新理念和外科相关的新证据和新推荐进行了解读。

The"2022 AHA/ACC/HFSA guideline for the management of heart failure"replaces the"2013 ACCF/AHA guideline for the management of heart failure"and the"2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure".The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent,diagnose and manage patients with heart failure.Heart failure remains a leading cause of morbidity and mortality globally.The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients.The recommendations present an evidence-based approach to manage patients with heart failure,with the intent to improve quality of care and align with patients’interests.New recommendations have been created when supported by published data.Value statements are provided for certain treatments with high-quality published economic analyses.This article summarized and interpreted the new concept of heart failure in 2022 guidelines,especially the new evidence and suggestions related to cardiac surgery.